This deposit contains the Author Accepted Manuscript (AAM) of the review article published in *Alimentary Pharmacology & Therapeutics*. The review synthesizes early clinical and mechanistic evidence on sorafenib and other oral targeted agents used in the treatment of hepatocellular carcinoma (HCC). It discusses the therapeutic rationale, emerging clinical data, safety considerations, and future research priorities related to targeted therapies. This AAM is archived in accordance with Wiley’s self‑archiving policy for subscription journals (postprint allowed after embargo). The Version of Record is available through the DOI provided below.
Chaparro et al. (Mon,) studied this question.